Pfizer Inc. (NYSE:PFE) Shares Sold by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,960 shares of the biopharmaceutical company’s stock after selling 9,888 shares during the period. J.W. Cole Advisors Inc.’s holdings in Pfizer were worth $2,517,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Olistico Wealth LLC purchased a new stake in Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer during the 2nd quarter valued at about $29,000. Quarry LP purchased a new stake in shares of Pfizer in the second quarter valued at about $31,000. Financial Connections Group Inc. acquired a new stake in Pfizer during the second quarter worth about $34,000. Finally, ESL Trust Services LLC purchased a new position in Pfizer during the first quarter worth about $37,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Barclays increased their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 0.7 %

Shares of NYSE:PFE opened at $28.45 on Monday. The firm has a market capitalization of $161.21 billion, a PE ratio of -474.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm’s 50-day moving average is $29.08 and its two-hundred day moving average is $28.53.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.91%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.